Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals, Inc.
  6. News
  7. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RBC Cuts Price Target on Regeneron Pharmaceuticals to $647 From $658, Noting Risk to Eylea From Biosimilars; Sector Perform Kept

06/14/2022 | 07:26am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Regeneron Pharmaceuticals - NOVEL COSTIMULATORY BISPECIFIC ANTIBODY SHOWS ENCOURAGING A..
AQ
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
08/03WALL STREET STOCK EXCHANGE : A couple of hopes dashed
MS
08/03REGENERON PHARMACEUTICALS : Corporate Presentation August 2022
PU
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 799 M - -
Net income 2022 3 807 M - -
Net cash 2022 4 839 M - -
P/E ratio 2022 18,3x
Yield 2022 -
Capitalization 67 420 M 67 420 M -
EV / Sales 2022 5,30x
EV / Sales 2023 4,39x
Nbr of Employees 10 715
Free-Float 80,5%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 630,63 $
Average target price 676,32 $
Spread / Average Target 7,24%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375
GENMAB A/S-2.51%22 993